Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy
Rebeka Sultana(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Claire Hawkes(University of Warwick), Stephen Chan(Heidelberg University), Rachel Abbotts(University of Nottingham), Nada Albarakati(University of Nottingham), Tarek M.A. Abdel-Fatah(University of Nottingham), Graham Ball(Computer Algorithms for Medicine), Ian O. Ellis(University of Nottingham), Claire Seedhouse(University of Nottingham)
Cited by 101
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639